Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

778.48 +3.36 (+0.43%)
Streaming Delayed Price Updated: 10:06 AM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly: What Lepodisiran Could Mean For This Big Pharma Play
Lepodisiran is being developed by biotech giant Eli Lilly & Co. Here’s the tale of this new drug, how it could help millions, and how this furthers the “less-is-more” strategy that will make Lilly the... 
Via Talk Markets
Topics Stocks / Equities
2 Top Growth Stocks to Buy and Hold for the Next 20 Years
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Topics Economy Intellectual Property
Exposures Economy Intellectual Property
3 Growth ETFs to Buy With $500 and Hold
It doesn't take deep pockets to build a diversified growth portfolio. 
Via The Motley Fool
Topics ETFs
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. 
Via Investor's Business Daily
Topics Government
Exposures Political
US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert
U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs. 
Via Benzinga
Topics Government
Exposures Political
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption
On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 
Via Stocktwits
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Sangamo Therapeutics Stock Surges After The Bell: What's Going On?
Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co. 
Via Benzinga
Stock Market Sell-Off: The 9 Best Stocks to Buy Now in April (2025)
Via The Motley Fool
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Why April Could Be a Huge Month for Eli Lilly Stock
Via The Motley Fool
Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?
Via The Motley Fool
Topics Economy
Exposures Economy
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Why Major Pharmaceutical Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Why Hims & Hers Health Stock Soared Tuesday
Via The Motley Fool
Topics Stocks
Exposures US Equities
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Product Safety Supply Chain
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Check Out What Whales Are Doing With LLY
Via Benzinga
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles. 
Via Investor's Business Daily
Topics Workforce
Exposures COVID-19 Layoff Product Safety
If Nearly Half of S&P 500 Stocks Are Up in 2025, Then Why Is the Index Down 5%?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns. 
Via The Motley Fool
Exposures Product Safety
The Vanguard S&P 500 ETF Is Sinking, but This Wall Street Analyst Predicts It Will Soar 168% by 2030
Via The Motley Fool
Topics ETFs Economy Stocks
Exposures Economy US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.